Patent: 10,626,463
✉ Email this page to a colleague
Summary for Patent: 10,626,463
| Title: | Biomarker associated with risk of melanoma reoccurrence |
| Abstract: | The present invention provides a method of predicting the risk of reoccurrence of melanoma in a patient from whom melanoma tissue was previously removed which comprises the following: a. obtaining a RNA-containing sample of the previously removed melanoma tissue containing RNA from the patient; b. treating the sample to determine from the RNA contained in the sample the level of expression of a plurality of preselected genes; and c. comparing the level of expression of each gene of the plurality of pre-selected genes to a predetermined reference level of expression for each such gene; wherein a higher level of expression of the plurality of pre-selected genes in the sample as compared with the predetermined reference level of expression of such genes indicates that the patient has a reduced risk of reoccurrence of melanoma. |
| Inventor(s): | Saenger; Yvonne (New York, NY), Sivendran; Shanthi (Gettysburg, PA), Chang; Rui (New York, NY), Difeo; Analisa (Port Washington, NY) |
| Assignee: | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (New York, NY) |
| Application Number: | 14/419,409 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,626,463
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | IMLYGIC | talimogene laherparepvec | For Injection | 125518 | 10/27/2015 | ⤷ Try a Trial | 2032-08-03 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
